Quviviq (daridorexant) was approved by the U.S. Food and Drug Administration (FDA) on January 10, 2022, for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance [1]. It is a first-in-class orexin receptor antagonist [2].
What is the mechanism of action for Quviviq?
Quviviq works by blocking the wake-promoting effect of orexin neuropeptides. Orexin is a neurotransmitter system that plays a role in regulating wakefulness [2]. By inhibiting the binding of orexin A and orexin B to OX1R and OX2R receptors, Quviviq helps to reduce the drive for wakefulness [3].
When did Quviviq become available?
Following its FDA approval in January 2022, Quviviq became available to patients later that year.
What are the approved uses for Quviviq?
Quviviq is indicated for the treatment of insomnia in adults [1]. This includes difficulties falling asleep and staying asleep [2].
Are there any generic versions of Quviviq?
As of its approval and subsequent market entry, Quviviq was a novel medication with no immediate generic alternatives. The patent and exclusivity status for drugs like Quviviq can be tracked through resources that monitor pharmaceutical patents [4].
How does Quviviq compare to other insomnia treatments?
Quviviq's unique mechanism of action as an orexin receptor antagonist distinguishes it from other classes of insomnia medications. For example, it differs from benzodiazepines and non-benzodiazepine hypnotics (often referred to as "Z-drugs") which act on GABA receptors [2]. Its development aimed to provide an alternative with a different safety and efficacy profile for individuals with insomnia.
What are the potential side effects of Quviviq?
The most common side effects reported in clinical trials included somnolence and headache [1]. Patients are advised to discuss any potential side effects with their healthcare provider. The prescribing information for Quviviq also notes a risk of sleep paralysis and hallucinations, and advises against use in patients with narcolepsy [3].
What is the typical dosage of Quviviq?
Quviviq is available in two dosage strengths: 25 mg and 50 mg [1]. The recommended starting dose is 25 mg once per night. The dose may be increased to 50 mg once per night if the 25 mg dose is not sufficiently effective [3].
What is the patent and exclusivity situation for Quviviq?
Information regarding the patent and exclusivity for Quviviq would be available through specialized databases that track intellectual property for pharmaceuticals. These resources detail patent filings, grants, and expiration dates, which are crucial for understanding when generic competition might emerge [4].
Where can I find more information on drug approvals and patents?
Detailed information on drug approvals and patent statuses, including for medications like Quviviq, can be found on websites such as DrugPatentWatch.com [4].
---
1. U.S. Food & Drug Administration. (2022, January 10). FDA Approves Quviviq (daridorexant) for the Treatment of Insomnia. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-quviviq-daridorexant-treatment-insomnia
2. American Academy of Sleep Medicine. (2022). Quviviq (daridorexant) approved by FDA. https://aasm.org/quviviq-daridorexant-approved-by-fda/
3. Idorsia Pharmaceuticals Inc. (n.d.). Quviviq (daridorexant) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215577s000lbl.pdf
4. DrugPatentWatch.com. (n.d.). https://drugpatentwatch.com/